Cartesian Therapeutics (RNAC) Non-Current Deferred Tax Liability (2022 - 2026)

Cartesian Therapeutics (RNAC) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $6.9 million in Q1 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability fell 56.95% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 56.95% decrease from a year earlier, with the FY2025 full-year figure at $6.9 million, down 56.95% from the prior year.
• Non-Current Deferred Tax Liability for Q1 2026 stood at $6.9 million, roughly flat from $6.9 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for RNAC reached as high as $44.0 million in Q4 2023 and fell as low as $3.3 million in Q4 2022.
• Historically, Non-Current Deferred Tax Liability has averaged $15.8 million across 5 years, with a median of $15.9 million in 2024.
• Across the five-year window, Non-Current Deferred Tax Liability surged 1252.47% in 2023 and slumped 63.34% in 2024, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $3.3 million in 2022, then jumped by 1252.47% to $44.0 million in 2023, then slumped by 63.34% to $16.1 million in 2024, then slumped by 56.95% to $6.9 million in 2025, then changed by 0.0% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $6.9 million in Q1 2026, $6.9 million in Q4 2025, and $16.1 million in Q3 2025.